Treatment of adult Burkitt lymphoma with the CALGB 1002 protocol: a single center experience in Jordan

Mohammad Ma’koseh; Rula Amarin; Faris Tamimi; Baha’ Sharaf; Alaa Abufara; Omar Shahin; Mohammed K. M. Manassra; Khalid Halahleh

doi:10.5045/br.2021.2021116

추천

검색

자료유형: 학술저널

저자정보: Mohammad Ma’koseh (Department of Medical Oncology King Hussein Cancer Center Amman Jordan) Rula Amarin (Department of Medical Oncology King Hussein Cancer Center Amman Jordan) Faris Tamimi (Department of Medical Oncology King Hussein Cancer Center Amman Jordan) Baha’ Sharaf (Department of Medical Oncology King Hussein Cancer Center Amman Jordan) Alaa Abufara (Department of Medical Oncology King Hussein Cancer Center Amman Jordan) Omar Shahin (Department of Medical Oncology King Hussein Cancer Center Amman Jordan) Mohammed K. M. Manassra (Department of Medical Oncology King Hussein Cancer Center Amman Jordan) Khalid Halahleh (Department of Medical Oncology King Hussein Cancer Center Amman Jordan)

저널정보: 대한혈액학회 Blood Research Blood Research Vol.56 No.4

발행연도: 2021.12

수록면: 279 - 284 (6page)

DOI: 10.5045/br.2021.2021116

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background The treatment of adult Burkitt lymphoma with pediatric-based chemotherapy protocols usually results in high cure rates, although with significant toxicity. We report our experience with the Cancer and Leukemia Group B1002 (CALGB 1002) protocol. Methods The files of adult patients diagnosed with Burkitt lymphoma and treated with the CALGB 1002 protocol at King Hussein Cancer Center between 2008 and 2017 were reviewed. Baseline demographics, clinical laboratory features, treatment details, and responses were collected. The correlations between clinical and laboratory variables with event-free survival (EFS) and overall survival (OS) were determined by univariate and multivariate analyses using backward stepwise Cox regression models. EFS and OS were plotted using Kaplan?Meier curves. Results This study included 19 patients with a median age of 33 years (range, 19?65). Eleven (58%) and two (10.5%) patients had advanced-stage and central nervous system disease, respectively. Among 106 administered cycles, the median interval between cycles was 23 days (range, 19?84 days). Sixteen patients (84%) achieved a complete response. After a median follow-up of 40.8 months, the 3-year EFS and OS rates were 78.95%. Patients with a low-risk International Prognostic Index (IPI) had better survival than those with intermediate-or high-risk IPI. Grade III?IV hematological toxicities occurred in 88% of patients, while 73% had grade III?IV mucositis. Conclusion In adult Burkitt lymphoma, the CALGB 1002 protocol provides high cure rates and can be administered promptly, but is associated with significant toxicity. Risk-adapted approaches and other, less toxic, chemotherapeutic regimens should be considered.

#Burkitt lymphoma #CALGB 1002 #International Prognostic Index

참고문헌 (25)

참고문헌 신청

Dunleavy K / 2018 / Approach to the diagnosis and treatment of adult Burkitt’s lymphoma / J Oncol Pract 14:665~671

Morton LM / 2006 / Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001 / Blood 107:265~276

Kalisz K / 2019 / An update on Burkitt lymphoma : a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence / Insights Imaging 10:56

Kasamon YL / 2004 / Treatment advances in adult Burkitt lymphoma and leukemia / Curr Opin Oncol 16:429~435

Jacobson C / 2014 / How I treat Burkitt lymphoma in adults / Blood 124:2913~2920

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!